Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Jinmei Su, Mengtao Li, Lan He, Dongbao Zhao, Weiguo Wan, Yi Liu, Jianhua Xu, Jian Xu, Huaxiang Liu, Lindi Jiang,

BioDrugs

Abstract

References